Pfizer Inc. PFE
29.18 USD -0.05 (-0.19%)
Nov 10, 2026, 1:57 PM EST
28.95 Day range 29.29
23.67 52-week range 30.79
- YTD
- +17.17%
- 1 year
- +19.62%
News
fool.com Pfizer Hits a New 52-Week High. Here's Why It's Not Too Late to Buy the Stock Pfizer's recently launched and acquired products have been generating impressive growth. The stock is up big this year, but its valuation remains modest based on analyst expectations.
benzinga.com Medicus Pharma Unveils Capital Strategy Centered On Novel Cancer Pipeline Medicus Pharma advances its Pfizer-partnered cancer asset and plans a $135 million SkinJect SPAC deal while reducing quarterly operating expenses.
fool.com Forget Lilly and Novo: Pfizer Is Planning a Wave of Phase 3 Obesity Trials Eli Lilly is the leader in the GLP-1 weight-loss space, with Novo Nordisk working hard to regain lost market share. Pfizer had to drop its GLP-1 drug candidate, but quickly pivoted by acquiring a new…
benzinga.com Guggenheim Maintains Buy on Pfizer, Raises Price Target to $33 Guggenheim analyst Vamil Divan maintains Pfizer (NYSE:PFE) with a Buy and raises the price target from $31 to $33.
defenseworld.net Pfizer Inc. $PFE Shares Newly Acquired by Associated Banc Corp Associated Banc Corp bought a new stake in Pfizer Inc. (NYSE: PFE) in the undefined quarter, according to its most recent disclosure with the SEC. The fund bought 100,353 shares of the…
benzinga.com Scotiabank Maintains Sector Outperform on Pfizer, Raises Price Target to $35 Scotiabank analyst Louise Chen maintains Pfizer (NYSE:PFE) with a Sector Outperform and raises the price target from $33 to $35.
benzinga.com Citigroup Maintains Neutral on Pfizer, Raises Price Target to $30 Citigroup analyst Geoff Meacham maintains Pfizer (NYSE:PFE) with a Neutral and raises the price target from $27 to $30.- benzinga.com RBC Capital Maintains Sector Perform on Pfizer, Raises Price Target to $28 RBC Capital analyst Trung Huynh maintains Pfizer (NYSE:PFE) with a Sector Perform and raises the price target from $25 to $28.
fool.com Pfizer: 3 Key Takeaways for Long-Term Investors Pfizer raised 2026 revenue guidance to $62 billion to $64 billion. Launched and acquired products achieved 32% operational revenue growth in Q3.
benzinga.com Amazon, Pfizer, Eaton And A Financial Stock On CNBC's ‘Final Trades' On CNBC's “Halftime Report Final Trades,” Joshua Brown, co-founder and CEO of Ritholtz Wealth Management, picked Amazon.com, Inc. (NASDAQ:AMZN).
benzinga.com Amazon, Pfizer, Eaton And A Financial Stock On CNBC’s ‘Final Trades’ CNBC's Final Trades: Brown picked Amazon, Lebenthal chose BlackRock, Snipe backed Eaton, and Terranova recommended Pfizer.
benzinga.com Nasdaq Jumps Over 200 Points as Chip Stocks Gain: Fear & Greed Index Remains in ‘Extreme Fear’ Zone Markets closed mixed as CNN Fear & Greed stayed at 19 (Extreme Fear); Nasdaq rose 0.83%, Dow fell, Apple dropped and Aehr surged 26%.
marketbeat.com Pfizer Q3 Earnings Call Highlights Pfizer NYSE: PFE reported third-quarter 2026 revenue of $16.6 billion and raised its full-year outlook, citing growth in non-COVID products, contributions from launched and acquired medicines, and…
seekingalpha.com Pfizer Inc. (PFE) Q3 2026 Earnings Call Transcript Pfizer Inc. ( PFE ) Q3 2026 Earnings Call November 3, 2026 10:00 AM EST Company Participants Francesca DeMartino - Chief Investor Relations Officer Albert Bourla - Chairman of the Board & CEO Cecile…
youtube.com Pfizer CEO Albert Bourla on Q3 earnings, patent expirations, obesity drug market CNBC's Annika Kim Constantino and Albert Bourla, Pfizer CEO, join 'The Exchange' to discuss Pfizer's Q3 earnings, patent expirations, and more.
247wallst.com Moderna Climbs 5% Ahead of Earnings, Pfizer Eases Despite Raised Outlook, Merck Slides 2% Despite New Phase 3 Trial Three of the biggest names in pharma and vaccines are trading against their own headlines. Moderna (NASDAQ:MRNA | MRNA Price Prediction) stock is at $231.
247wallst.com Roth IRA vs. Taxable Account: How Much of $11,400 in Dividends Would You Keep? Six high-yield stocks, one portfolio, and two very different tax bills waiting at the end of each year. Where you hold these positions matters far more than most investors realize before they file.
benzinga.com Nasdaq Surges 1%; Pfizer Posts Upbeat Q3 Earnings U.S. stocks traded mixed midway through trading, with the Nasdaq Composite gaining around 1% on Tuesday.
benzinga.com Nasdaq Surges 1%; Pfizer Posts Upbeat Q3 Earnings U.S. stocks were mixed as Nasdaq gained 1%; Pfizer beat Q3 estimates and raised 2026 guidance, while oil, gold and European shares fell.
247wallst.com UPS's $5.4 Billion Dividend Bill Exceeded Its Free Cash Flow. Is the Payout at Risk? Four stocks are paying out billions in dividends that their cash flows can barely support, and the gap between what investors expect and what the business can actually deliver keeps widening.
zacks.com Q3 Earnings & JOLTS Report on Midterm Voting Day Early voting has seen some 60+ million Americans take to the ballot this year -- far ahead of normal levels of midterm voting.
zacks.com Pfizer (PFE) Reports Q3 Earnings: What Key Metrics Have to Say Although the revenue and EPS for Pfizer (PFE) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall…
benzinga.com Pfizer Q3 2026 Earnings Call Transcript Pfizer (NYSE:PFE) reported third-quarter financial results on Tuesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…
benzinga.com Non-COVID Portfolio Steps Up: Pfizer Outpaces Consensus and Hikes Guidance Pfizer beats Q3 revenue and profit forecasts on oncology and non-COVID drug growth, raising its full-year 2026 sales and EPS outlook.
zacks.com PFE Beats Q3 Earnings & Sales Estimates, Raises 2026 Guidance Pfizer beats third-quarter earnings and revenue estimates, driven by strong non-COVID product sales, and increases its 2026 guidance.
fool.com Pfizer's Eliquis Price Gains Cover COVID Drop: Rapid Earnings Reaction Revenue was flat at $16.6 billion, with COVID and Prevnar sales falling while Eliquis, Padcev, Vyndaqel, Nurtec, and Lorbrena grew. Pfizer raised its full-year revenue and adjusted EPS guidance.
schaeffersresearch.com Stock Futures Mixed as Midterm Elections Get Underway Stock futures are mixed ahead of Midterm elections as chip stocks bounce
zacks.com Pfizer (PFE) Surpasses Q3 Earnings and Revenue Estimates Pfizer (PFE) came out with quarterly earnings of $0.87 per share, beating the Zacks Consensus Estimate of $0.72 per share. This compares to earnings of $0.87 per share a year ago.
fool.com Pfizer Beats Expectations in Q3 and Raises Its Guidance. Is the Stock Due for a Big Rally? Pfizer's numbers were strong in its most recent quarter, with both its top and bottom lines coming in better than analyst forecasts. The company experienced 32% growth from launched and acquired…
investopedia.com 5 Things Investors Need to Know About Tuesday's Markets Stock-market futures are mixed this morning, with the Dow pointing to a lower open after finishing yesterday the only leading index to manage a gain; voters are preparing for Election Day in the…
wsj.com Pfizer Raises Forecast on Momentum With New Products Pfizer boosted its guidance for the year, citing momentum in newly-launched and acquired products that helped offset declining sales for its Covid-19 vaccine and treatments.
barrons.com Pfizer Finds Life Beyond the Pandemic as Earnings Top Estimates Pfizer boosts full-year guidance on the back of its latest quarter, citing growth in non-Covid offerings and acquired products.
cnbc.com Pfizer hikes full-year outlook, taps company veteran as new CFO Pfizer reported third-quarter results that topped estimates and hiked its full-year outlook, citing its "strong year-to-date performance" and ongoing cost cuts. Pfizer also announced that Cecile…
reuters.com Pfizer raises 2026 forecast on strong demand for blood thinner Eliquis Nov 2 (Reuters) - Pfizer (PFE.N), opens new tab raised its annual profit and revenue forecasts on Tuesday, banking on strong demand for its blood thinner Eliquis. The U.S.
benzinga.com Pfizer Raises FY2026 Adj EPS Guidance from $2.80-$3.00 to $2.95-$3.05 vs $2.96 Est; Raises FY2026 Sales Guidance from $60.500B-$62.500B to $62.000B-$64.000B vs $62.166B Est Pfizer (NYSE:PFE) raises FY2026 Adj EPS guidance from $2.80-$3.00 to $2.95-$3.05 vs $2.96 analyst estimate. Raises FY2026 sales outlook from $60.500 billion-$62.500 billion to $62.000 billion-$64.000…- benzinga.com Pfizer Q3 Adj. EPS $0.87 Beats $0.72 Estimate, Sales $16.583B Beat $15.872B Estimate Pfizer (NYSE:PFE) reported quarterly earnings of $0.87 per share which beat the analyst consensus estimate of $0.72 by 19.18 percent. This is unchanged from the same period last year. The company…
businesswire.com Pfizer Reports Strong Third-Quarter 2026 Results And Raises 2026 Guidance NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) reported financial results for the third quarter of 2026 and raised its full-year 2026 guidance(2) for both Revenues and Adjusted(3) diluted EPS.…
benzinga.com Pfizer Appoints Cecile Guegan As CFO And EVP, Effective November 1, 2026 Cecile Guegan to lead Pfizer’s financial strategy as Chief Financial Officer with over 25 years of pharmaceutical finance experiencePfizer Inc. (NYSE:PFE) today announced that its Board of Directors…
businesswire.com Pfizer Appoints Cecile Guegan as Chief Financial Officer NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that its Board of Directors has unanimously appointed Cecile Guegan as Chief Financial Officer and Executive Vice President,…
benzinga.com Top Wall Street Forecasters Revamp Pfizer Expectations Ahead Of Q3 Earnings Pfizer Inc. (NYSE:PFE) will release its third quarter earnings report before the opening bell on Tuesday, Nov. 3.
benzinga.com Top Wall Street Forecasters Revamp Pfizer Expectations Ahead Of Q3 Earnings Pfizer will report Q3 earnings Nov. 3; analysts expect EPS to fall to $0.73 and revenue to $15.88B, while recent ratings remain mixed.
benzinga.com Nasdaq Dips Over 1% as Tech Stocks Fall: Investor Sentiment Weakens, Fear & Greed Index Moves to ‘Extreme Fear’ Zone CNN Fear & Greed fell to 23, signaling Extreme Fear, as tech stocks dragged Nasdaq down 1.07%; Dow rose 214 points amid U.S.-Iran diplomacy hopes.
benzinga.com Pfizer, Apple and 3 Stocks to Watch Heading Into Tuesday Pfizer and Keurig Dr Pepper report earnings; Apple, Palantir and AMD draw attention after results, guidance and trading moves.
benzinga.com Stock Market: Will S&P 500 Open Up or Down Today? Will the S&P 500 open higher? Polymarket odds dip to 45% as Wall Street navigates Election Day, AMD earnings, and a volatile oil market.
benzinga.com AMD, Shopify On Deck Tuesday As AI Spending, Merchant Growth Face Test Advanced Micro Devices headlines Tuesday’s reports, with investors looking for evidence that AI demand can withstand a sharp pullback in the stock. Shopify, Pfizer, Eaton, Marathon Petroleum and…
benzinga.com AMD Could Swing $90.7 Billion After Earnings Seven major companies are set to report earnings Tuesday, and options traders are pricing in significant stock moves. From Pfizer’s modest 4.14% implied move to Shopify’s 13.01% swing, here’s a…
benzinga.com How To Earn $500 A Month From Pfizer Stock Ahead Of Q3 Earnings Pfizer expects Q3 EPS of 73¢ and revenue of $15.88B; its 5.64% dividend yield requires ~$106,454 to generate $500 monthly.
benzinga.com Pfizer Cancer Therapy Shows Extended Progression-Free Survival in Multiple Myeloma Patients Pfizer reports positive Phase 3 ELREXFIO data showing reduced disease progression risk in relapsed or refractory multiple myeloma patients.
benzinga.com Pfizer Announces That Topline Results In The Phase 3 MagnetisMM-32 Trial Of ELREXFIO Demonstrated Clinically Meaningful And Statistically Significant Benefit For Patients Whose Disease Progressed After Anti-CD38 Therapy And Lenalidomide, With Median PFS Not Yet Reached Pfizer Inc. (NYSE:PFE) today announced topline results from the Phase 3 MagnetisMM-32 study evaluating ELREXFIO® (elranatamab) as monotherapy in adults with relapsed or refractory multiple myeloma…- benzinga.com Reported Saturday, Pfizer Presents Phase 2 25vPnC Infant Data At IDWeek 2026: Robust Responses To All 25 Serotypes, Including Five New, Safety Comparable To PREVNAR 20, No Related Serious Adverse Events Investigational vaccine shows strong immune responses in infants equivalent to PREVNAR 20 on shared serotypes and for five new serotypes, potentially offering the broadest protection against invasive…